NCT05005403 2025-10-28Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or BevacizumabAbbViePhase 1 Recruiting512 enrolled
NCT01552434 2025-10-14Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseM.D. Anderson Cancer CenterPhase 1 Active not recruiting155 enrolled
NCT05039801 2025-10-14IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsM.D. Anderson Cancer CenterPhase 1 Recruiting54 enrolled
NCT00405405 2025-05-06Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck CancerThomas Jefferson UniversityPhase 1 Completed13 enrolled
NCT04999761 2024-09-25AB122 Platform StudyTaiho Pharmaceutical Co., Ltd.Phase 1 Recruiting917 enrolled
NCT00023959 2013-02-07Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerNational Cancer Institute (NCI)Phase 1 Completed39 enrolled